EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice

Isabelle S Massart iD, Axell-Natalie Kouakou, Nathan Pelet, Pascale Lause, Olivier Schakman, Audrey Loumaye, Michel Abou-Samra, Louise Deldicque, Laure B Bindels, Sonia M Brichard, Jean-Paul Thissen

Journal of Cachexia, Sarcopenia and Muscle · 2024

DOI: 10.1002/jcsm.13454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Isabelle S Massart und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetes and Nutrition Unit, Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium. Hauptthemen laut MEDLINE: Cachexia, Receptors, Adiponectin, Inflammation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de la Recherche Scientifique - FNRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer cachexia is a life‐threatening, inflammation‐driven wasting syndrome that remains untreatable. Adiponectin, the most abundant adipokine, plays an important role in several metabolic processes as well as in inflammation modulation. Our aim was to test whether administration of AdipoRon (AR), a synthetic agonist of the adiponectin receptors, prevents the development of cancer cachexia and its related muscle atrophy.

Methods

The effect of AR on cancer cachexia was investigated in two distinct murine models of colorectal cancer. First, 7‐week‐old CD2F1 male mice were subcutaneously injected with colon‐26 carcinoma cells (C26) or vehicle (CT). Six days after injection, mice were treated for 5 days with AdipoRon (50 mg/kg/day; C26 + AR) or the corresponding vehicle (CT and C26). Additionally, a genetic model, the Apc Min /+ mouse, that develops spontaneously numerous intestinal polyps, was used. Eight‐week‐old male Apc Min/+ mice were treated with AdipoRon (50 mg/kg/day; Apc + AR) or the corresponding vehicle (Apc) over a period of 12 weeks, with C57BL/6J wild‐type mice used as controls. In both models, several parameters were assessed in vivo: body weight, grip strength and serum parameters, as well as ex vivo: molecular changes in muscle, fat and liver.

Results

The protective effect of AR on cachexia development was observed in both cachectic C26 and Apc Min /+ mice. In these mice, AR administration led to a significant alleviation of body weight loss and muscle wasting, together with rescued muscle strength ( P < 0.05 for all). In both models, AR had a strong anti‐inflammatory effect, reflected by lower systemic interleukin‐6 levels (−55% vs. C26, P < 0.001 and −80% vs. Apc mice, P < 0.05), reduced muscular inflammation as indicated by lower levels of Socs3 , phospho‐STAT3 and Serpina3n , an acute phase reactant ( P < 0.05 for all). In addition, AR blunted circulating levels of corticosterone (−46% vs. C26 mice, P < 0.001 and −60% vs. Apc mice, P < 0.05), the predominant murine glucocorticoid known to induce muscle atrophy. Accordingly, key glucocorticoid‐responsive factors implicated in atrophy programmes were—or tended to be—significantly blunted in skeletal muscle by AR. Finally, AR protected against lipid metabolism alterations observed in Apc Min /+ mice, as it mitigated the increase in circulating triglyceride levels (−38%, P < 0.05) by attenuating hepatic triglyceride synthesis and fatty acid uptake by the liver.

Conclusions

Altogether, these results show that AdipoRon rescued the cachectic phenotype by alleviating body weight loss and muscle atrophy, along with restraining inflammation and hypercorticism in preclinical murine models. Therefore, AdipoRon could represent an innovative therapeutic strategy to counteract cancer cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaReceptors, AdiponectinInflammationAnimalsMiceMaleDisease Models, AnimalCell Line, TumorMuscle, SkeletalNeoplasmsPiperidines

Stichwörter der Autor:innen

adiponectincachexiacancerinflammationskeletal muscle

Substanzen

AdipoRonReceptors, AdiponectinPiperidines

Autor:innen und Institutionen

  • Endocrinology, Diabetes and Nutrition Unit, Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
  • Institute of Neuroscience, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.

ORCID-Profile: Isabelle S Massart

Förderung

  • Fonds de la Recherche Scientifique - FNRS

Zitieren

APA

Massart, I. S., Kouakou, A. N., Pelet, N., Lause, P., Schakman, O., Loumaye, A., Abou-Samra, M., Deldicque, L., Bindels, L. B., Brichard, S. M., & Thissen, J. P. (2024). Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13454

Vancouver

Massart IS, Kouakou AN, Pelet N, Lause P, Schakman O, Loumaye A, et al. Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13454

BibTeX
@article{Massart2024,
  author = {Massart, Isabelle S and Kouakou, Axell-Natalie and Pelet, Nathan and Lause, Pascale and Schakman, Olivier and Loumaye, Audrey and Abou-Samra, Michel and Deldicque, Louise and Bindels, Laure B and Brichard, Sonia M and Thissen, Jean-Paul},
  title = {Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  doi = {10.1002/jcsm.13454}
}
Kostenlos starten →